Blastic Plasmacytoid Dendritic Cell Neoplasm: The European Perspective
- PMID: 32336424
- DOI: 10.1016/j.hoc.2020.01.012
Blastic Plasmacytoid Dendritic Cell Neoplasm: The European Perspective
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) has to be considered an orphan tumoral disease. BPDCN is a good model concerning the structuring and the organization of a concerted medical program on a nation-based, transnational, or international level. In 2019 in France the diagnosis process for BPDCN was clearly established. Two prospective clinical trials are ongoing. Because of the difficulties in diagnostic procedures and the rarity of the disease it is important that European countries collaborate to build a real European network to ensure the best and equitable medical care to all BPDCN patients.
Keywords: Allogeneic transplantation; BPDCN; Europe; International cooperation; Network; Orphan disease; Tagraxofusp.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure E. Deconinck belongs to the EBMT and SFH, is a member of a subcommittee of the Agence française de la Biomédecine, and participates in boards for Stemline therapeutics and ImunoGen.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources